| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3)：209-249.
|
| [2] |
National Institutes of Health, U．S. National Library of Medicine. A similar map is available for all studies in ClinicalTrials.gov[EB/OL]. [2021-06-20].
URL
|
| [3] |
|
| [4] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869)：805-816.
|
| [5] |
Bartlett J, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial[J]. Ann Oncol, 2019, 30(11)：1776-1783.
|
| [6] |
Yu KD, Cai YW, Shao ZM. De-escalation of five years adjuvant endocrine therapy duration in patients with ER-low positive (immunohistochemical 1% to 10%) early-stage breast cancer: A propensity-matched analysis from the prospectively maintained database[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.538. |
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
Yuan ZY, Huang JJ, Hua X, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER-2-positive: The sysucc-002 randomized clinical trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1003. |
| [11] |
Zhang J, Meng YC, Wang BY, et al. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1035. |
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
Zheng FC, Du F, Wang YS, et al. Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.529. |
| [16] |
Li J, Yu K, Pang D, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(16)：1774-1784.
|
| [17] |
|
| [18] |
|
| [19] |
Chen L, Shao ZM, Wang ZH, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1007. |
| [20] |
|